Abstract
Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.
Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel
Current Pharmaceutical Design
Title:Heart Rate as a Therapeutic Target in Angina Pectoris
Volume: 19 Issue: 9
Author(s): Emmanuel Androulakis, Dimitris Tousoulis, Nikolaos Papageorgiou, Anna Kontogeorgou, Alexandros Briasoulis, Marietta Charakida, Gerasimos Siasos, Evangelos Oikonomou, Katerina Siama, George Latsios and Christodoulos Stefanadis
Affiliation:
Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel
Abstract: Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.
Export Options
About this article
Cite this article as:
Androulakis Emmanuel, Tousoulis Dimitris, Papageorgiou Nikolaos, Kontogeorgou Anna, Briasoulis Alexandros, Charakida Marietta, Siasos Gerasimos, Oikonomou Evangelos, Siama Katerina, Latsios George and Stefanadis Christodoulos, Heart Rate as a Therapeutic Target in Angina Pectoris, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090003
DOI https://dx.doi.org/10.2174/1381612811319090003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Dietary Carbohydrates - Requirement and Recommendation in the Human Diet
Current Nutrition & Food Science Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry The Role of Platelets in Cardiovascular Disease: Molecular Mechanisms
Current Pharmaceutical Design Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Radionuclide Imaging in Patients with Ischemic Heart Failure
Current Medical Imaging The Emergence of Plasma Membrane Calcium Pump as a Novel Therapeutic Target for Heart Disease
Mini-Reviews in Medicinal Chemistry Impacts of Nanoparticles on Cardiovascular Diseases: Modulating Metabolism and Function of Endothelial Cells
Current Drug Metabolism Nutritional Antioxidants and Their Applications in Cardiometabolic Diseases
Infectious Disorders - Drug Targets Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antioxidant, Anti-Inflammatory and Anticancer Activities of the Methanolic Extract of Thottea siliquosa: An <i>In Vitro</i> and <i>In Silico</i> Study
Recent Patents on Anti-Cancer Drug Discovery Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Antithrombotic Therapy After TAVR
Current Vascular Pharmacology The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Prophylaxis of Cancer
Current Cancer Therapy Reviews Editorial (Thematic Issue: G-protein Coupled Receptors in Vascular Biology: Implication in Health and Disease)
Current Vascular Pharmacology Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Functions of S100 Proteins
Current Molecular Medicine